Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965

                              Keryx Biopharmaceuticals, Inc.
                           Selected Consolidated Financial Data
                    (In Thousands, Except Share and Per Share Amounts)

    Statements of Operations Information:

                                   Three Months Ended     Six Months Ended
                                        June 30,               June 30,
                                      (unaudited)            (unaudited)
                                    2009       2008        2009       2008

    License revenue            $  18,289     $  327   $  21,616     $  526
    Service revenue                   --         62           3         62
    Other reven
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 ... company developing next generation vaccines based on the ... into an exclusive worldwide licensing agreement with Astellas ... or prevention of any and all allergic diseases ... Therapeutics will receive an upfront payment of $300 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today launched the ... relationship between weight management and the microbiome. The study uses the ResearchKit framework, designed ... iPhone app. , The uBiome app is available as a free download from the ...
(Date:10/8/2015)... , Oct. 8, 2015  Genetic testing for mutations ... the identification of more couples at risk of having ... presented today at the 2015 American Society of Human ... in Baltimore, Maryland . The study ... (NYSE: DGX ) are presenting at the conference ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
Breaking Biology Technology:
... ), focused on discovering, developing and,commercializing treatments for diabetes and ... -- 18th Annual Wachovia Nantucket Equity Conference on Monday, ... (Eastern Time) at The White Elephant in Nantucket ... Conference on Thursday, June 26, 2008 ...
... and Advance,Healthcare, WASHINGTON, June 16 The ... Act (HIPAA) is having a,negative impact on the ... that benefit society, says a newly-released report by ... Barriers to,Research and Discovery describes the unintended disruptive ...
... ROCKVILLE, Md., June 16 Novavax, Inc.,(Nasdaq: NVAX ... Singhvi, President and Chief Executive Officer, will be presenting ... on June 24, 2008 at,The ANdAZ Hotel in London, ... strategy, research and development progress. A link to the ...
Cached Biology Technology:
(Date:10/7/2015)... , October 8, 2015 --> ... for Fingerprint Cards (FPC) during third quarter 2015 amounted to ... of around 860 MSEK that was communicated 20 August 2015. ... further strengthened delivery capacity and a continued growing demand for ... is estimated to be higher than during the third quarter. ...
(Date:10/6/2015)... , Oct. 6, 2015  Maverix Biomics, Inc., ... enhancements to its software portfolio with the debut ... for differential expression in eukaryotes. The software is ... a cloud-based genomic analysis solution that leverages proven ... from next-generation sequencing efforts. Garry Nolan,s ...
(Date:10/1/2015)... 2015  Biometrics includes diverse set of technologies ... such as fingerprints, eye retinas, facial patterns, voice ... technology has been constantly increasing in ... In addition to the most prominent popular method ... means of biometric authentication are rapidly gaining traction ...
Breaking Biology News(10 mins):
... global water crisis that already has left almost 800 million ... many more in the years ahead -- are the topic ... Chemical & Engineering News . C&EN is the weekly newsmagazine ... Alex Scott, C&EN,s senior editor for Europe, points out ...
... To make the inherent bitterness of cocoa in chocolate ice ... sugar. Yet, bitterness is an integral part of the complex ... August issue of the Journal of Dairy Science , ... form tolerate twice the amount of bitter ingredients in chocolate ...
... Mere months after porcine epidemic diarrhea virus (PEDV) ... University of Minnesota researchers have developed a PEDV rapid ... available now, provides a way to quickly and cost-effectively ... Characterized by acute diarrhea and vomiting, a PEDV outbreak ...
Cached Biology News:
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
EPH electrode, cathode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... tissue array is designed for rapidly ... in extensive panels of different types ... kidney, liver, lung, muscle, spleen and ... charged glass slide. Each tissue ...
Rat Normal Multiple Tissue Array 1 slide...
Biology Products: